Lexicon Pharmaceuticals (LXRX) Non Operating Investment Income (2010 - 2022)
Lexicon Pharmaceuticals (LXRX) reported Non Operating Investment Income of -$27000.0 for Q1 2022, down 150.94% on a QoQ basis from $53000.0 in Q2 2010.
Lexicon Pharmaceuticals (LXRX) has 2 years of Non Operating Investment Income data on file, last reported at -$27000.0 in Q1 2022.
- Quarterly Non Operating Investment Income changed N/A year-over-year to -$27000.0 in Q1 2022, while the trailing twelve-month figure through Mar 2022 was -$27000.0 (changed N/A YoY) and the FY2010 annual result came in at $141000.0, down 87.98% from the prior year.
- Non Operating Investment Income retreated to -$27000.0 in Q1 2022 per LXRX's latest filing, from $53000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at -$27000.0 in Q1 2022 and bottomed at -$27000.0 in Q1 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Lexicon Pharmaceuticals | 872.52 Mn | 701.87 Mn | 20.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -27,000.00 |
| Mar 31, 2022 | -27,000.00 |
| Jun 30, 2010 | 53,000.00 |
| Jun 30, 2010 | 53,000.00 |